# US 2017/0283804 A1 · Antisense compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283804 A1
- Document ID: US20170283804A1
- Status: Published application
- Kind: A1
- Application number: 15/510,750
- Filed: 2015-09-21
- Published: 2017-10-05
- Earliest claimed: 2014-09-19
- Assignees: Ionis Pharmaceuticals, Inc.
- Applicants: Ionis Pharmaceuticals, Inc.
- Inventors: Erich Koller; Aaron J. Donner; Punit P. Seth; C. Frank Bennett
- Web page: https://patentgrep.com/patent/US20170283804A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12Q 1/68: involving nucleic acids
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2320/31: Combination therapy
- C12N 2320/35: based on a specific dosage / administration regimen
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods for sensitizing a cell for modulation by oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method of reducing the amount or activity of a target nucleic acid in a liver cell comprising first contacting the liver cell with fingolimod, and subsequently contacting the cell with an oligomeric compound; and thereby reducing the amount or activity of the target nucleic acid in a the liver cell.

### Claim 4 (depends on 3)

The method of claim 3, wherein the liver cell has received from 1 to 11 doses of fingolimod prior to administration of the oligomeric compound.

### Claim 5 (depends on 3)

The method of claim 3, wherein theliver cell has received 1 dose of fingolimod prior to administration of the oligomeric compound.

### Claim at position 5

6-7. (canceled)

### Claim 8 (depends on 3)

The method of claim 3 wherein the liver cell receives one dose of fingolimod per day for from 1 to 11 days prior to administration of the oligomeric compound.

### Claim 9 (depends on 3)

The method of claim 3, wherein the liver cell is in vitro.

### Claim 10 (depends on 3)

The method of claim 3, wherein the cell is in an animal.

### Claim at position 9

11-14. (canceled)

### Claim 15 (depends on 3)

The method of claim 3, wherein the oligomeric compound is an antisense oligonucleotide.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide is an RNase H based antisense compound.

### Claim 17 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide comprises at least one modified nucleoside.

### Claim at position 13

18-20. (canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide has a sugar motif comprising:
a 5′-region consisting of 2-8 linked 5′-region nucleosides, wherein at least two 5′-region nucleosides are modified nucleosides and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;
a 3′-region consisting of 2-8 linked 3′-region nucleosides, wherein at least two 3′-region nucleosides are modified nucleosides and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; and
a central region located between the 5′ and 3′-regions consisting of 8-10 central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified deoxynucleoside, wherein the 5′-most central region nucleoside is an unmodified deoxynucleoside and the 3′-most central region nucleoside is an unmodified deoxynucleoside.

### Claim 22 (depends on 21)

The method of claim 21, wherein the 5′-region consists of from 2 to 5 linked 5′-region nucleosides and the 3′-region consists of from 2 to 5 linked 3′-region nucleosides.

### Claim 23 (depends on 21)

The method of claim 21, wherein the 5′-region consists of 3 linked 5′-region nucleosides, the 3′-region consists of 3 linked 3′-region nucleosides and the central region consists of 10 central region nucleosides.

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the 5′-region consists of 5 linked 5′-region nucleosides, the 3′-region consists of 5 linked 3′-region nucleosides and the central region consists of 10 central region nucleosides.

### Claim at position 19

26-32. (canceled)

### Claim 33 (depends on 15)

The method of claim 15, wherein the central region consists of 10 linked central region nucleosides.

### Claim 34 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide consists of 14 to 26 linked nucleosides.

### Claim 35 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide consists of 16 to 20 linked nucleosides.

### Claim 36 (depends on 21)

The method of claim 21, wherein each modified nucleoside independently comprises a 2′-substituted sugar moiety or a bicyclic sugar moiety.

### Claim at position 24

37-39. (canceled)

### Claim 40 (depends on 36)

The method of claim 36, wherein each 2′ sub stituent is independently selected from among: a halogen, OCH3, OCF3, OCH2CH3, OCH2CF3, OCH2—CH═CH2, O(CH2)2—OCH3 (MOE), O(CH2)2—O(CH2)2—N(CH3)2, OCH2C(═O)—N(H)CH3, OCH2C(═O)—N(H)—(CH2)2—N(CH3)2, and OCH2—N(H)—C(═NH)NH2.

### Claim 41 (depends on 40)

The method of claim 40, wherein the at least one 2′-substituted sugar moiety comprises a 2′-MOE sugar moiety.

### Claim at position 27

42-47. (canceled)

### Claim 48 (depends on 36)

The method of claim 36, wherein each bicyclic sugar moiety is independently an (S)-cEt sugar moiety or an LNA sugar moiety.

### Claim at position 29

49-50. (canceled)

### Claim 51 (depends on 15)

The method of claim 15, wherein each internucleoside linkage of the antisense oligonucleotide is, independently, a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.

### Claim at position 31

52-53. (canceled)

### Claim 54 (depends on 51)

The method of claim 51, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim at position 33

55-61. (canceled)

### Claim 62 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide is at least 95% complementary to a target nucleic acid.

### Claim 63 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide is 100% complementary to a target nucleic acid.

### Claim at position 36

64-66. (canceled)

### Claim 67 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide comprises a conjugate, and wherein the conjugate is not an antibody.

### Claim at position 38

68-69. (canceled)
